0TDD Stock Price and Chart — LSE:0TDD

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

Key facts today

Novo Nordisk's shares fell over 25% in March, marking the biggest drop since July 2002, amid rising investor worries about competition from Eli Lilly's Zepbound, which outperformed Wegovy in trials.

Novo Nordisk's daily hemophilia treatment, Alhemo, competes with Sanofi's Qfitlia, which is given every two months, showcasing the competitive market for hemophilia therapies.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.